12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zohydro ER hydrocodone bitartrate regulatory update

In a letter to FDA Commissioner Margaret Hamburg, a group of 28 state attorneys general requested that the agency reconsider its approval of Zogenix's Zohydro ER hydrocodone bitartrate or set a "rigorous" timeline for the product to be reformulated to be abuse deterrent. Last month, the company partnered with Altus Formulation Inc. (Montreal, Quebec) to develop abuse-deterrent formulations of the product,...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >